BioCentury
ARTICLE | Clinical News

Leukine sargramostim: Phase II data

July 1, 2013 7:00 AM UTC

The open-label, U.S. Phase II E1608 trial in 245 patients showed that subcutaneous Leukine sargramostim plus IV Yervoy ipilimumab led to a 1-year OS of 68.9% vs. 52.9% for IV Yervoy alone. Tumor shrinkage rates were comparable between arms (11-14%). The combination led to fewer lung and gastrointestinal toxicities vs. Yervoy alone. There were 2 deaths that were possibly treatment-related in the combination arm vs. 7 in the Yervoy alone arm. ...